Skip to main content
Clinical Trials/JPRN-jRCT1030210427
JPRN-jRCT1030210427
Not Yet Recruiting
Phase 1

Behavioral activation program for reducing depressive symptoms among the bereaved of cancer patients

Asai Mariko0 sites20 target enrollmentNovember 16, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
depressive symptoms
Sponsor
Asai Mariko
Enrollment
20
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 16, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Asai Mariko

Eligibility Criteria

Inclusion Criteria

  • 1\. Bereaved whose family had died of cancer , aged 20 years or older, and 3 years or more after bereavement at the time of enrollment
  • 2\. Bereaved with depression (PHQ\-9 of 10 or higher )
  • 3\. Bereaved who can comply with total 7 sessions program
  • 4\. Bereaved who are able to speak Japanese
  • 5\. Bereaved who are able to provide written informed consent
  • (in case when participant in an online program added to the inclusion criteria)
  • 6\. Bereaved whose internet environment is capable of identifying appropriate use of online service (Wi\-Fi internet access is protected by password , protective software of personal computer is up\-to\-date ect.)
  • 7\. Bereaved who are able to keep promise of appropriate use of online service (prohibition on video recording and secondary use of program tool ect.)

Exclusion Criteria

  • 1\.Bereaved with severe physical or psychological symptoms (cognitive dysfunction, impaired consciousness, severe depression with psychotic symptoms, imminent suicidal ideation, and history of suicide attempt)
  • 2\. Bereaved who have received psychological intervention, such as behavioral activation, by mental health professionals before enrollment
  • 3\.Those who are deemed to have difficulty in participating this program by the researcher due to other reasons.

Outcomes

Primary Outcomes

Not specified

Similar Trials